You just read:

New Novartis medicine Adakveo® (crizanlizumab-tmca) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell disease

News provided by

Novartis Pharmaceuticals Corporation

Nov 15, 2019, 16:32 ET